EE478 Using Real World Evidence to Generate Cost-Effectiveness Analysis of Fibrinolytic Therapy in Patients with ST-Segment Elevation Myocardial Infarction in a Limited Resource Country

K Trerayapiwat,P Jinatongthai,P Vathesatogkit,P Sritara,N Paengsai,P Dilokthornsakul,S Nathisuwan,L Le,N Chaiyakunapruk

doi:10.1016/j.jval.2022.04.726

EE478 Using Real World Evidence to Generate Cost-Effectiveness Analysis of Fibrinolytic Therapy in Patients with ST-Segment Elevation Myocardial Infarction in a Limited Resource Country

K Trerayapiwat, P Jinatongthai + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2022.04.726

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jun 25, 2022
License type: publisher-specific-oa

Affiliation: Ubon Ratchathani University, Naresuan University, Mahidol University

#Percutaneous Coronary Intervention For Treatment #National Electronic Database + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Due to limited access to primary percutaneous coronary intervention for treatment of ST-segment elevation myocardial infarction (STEMI) in low- and middle-income countries, fibrinolysis is the vital alternative treatment. We aimed to assess cost-effectiveness of tenecteplase (TNK) as compared to streptokinase (SK) for STEMI management using real world outcomes data obtained from a national electronic database.

Full Text